Key Takeaways
- • Yicura BioMed, a Hong Kong Science Park-based biotech start-up, is heading toward an initial public offering in Hong Kong "as soon as practicable," according to CEO Xian Jin in an interview with the South China Morning Post.
- • Jin says developing a new drug for the Chinese market takes an average of eight years and 1 billion yuan (US$150 million), with a 90 to 95 per cent failure rate from preclinical stages through phase 1 trials.
- • Jin argues Hong Kong's biotech ecosystem needs more "patient capital" and more talent able to commercialise research and development.
- • Yicura's recent funding activity includes a Series B round led by Gobi Partners and a dual capital and industrial strategy centred on its ICVAX immunotherapy platform.
- • Other 2026 Hong Kong biotech listings, including Axiom Biosciences' planned HKEX filing, point to a broader trend of global and local biotech firms choosing Hong Kong for listings.
Summary
Jin described biotech start-up fundraising in Hong Kong as "never an easy game to play." He cited industry benchmarks for developing a new drug for the Chinese market: an average of eight years and 1 billion yuan (US$150 million), with a 90 to 95 per cent failure rate in the progression from preclinical stages to phase 1 trials.
Yicura's recent financing activity was covered in publisher materials. A Series B round was led by Gobi Partners, and the company has described a dual capital and industrial strategy built around ICVAX, which it says it is moving from early clinical validation toward efficacy studies. Publisher commentary notes that biomedical start-ups need patient capital to navigate the "Valley of Death" between early research and commercialisation.
The Yicura IPO plan sits within a wider shift in Hong Kong biotech listings. According to a publisher roundup, 29 biotech companies listed across Hong Kong, Shanghai, Seoul, Tokyo and Sydney in 2026, raising US$2.70 billion combined. Coverage of the biotech IPO boom attributes it partly to structural exchange reforms at HKEX, including a faster IPO vetting process. Axiom Biosciences, a US-based biotech, has also announced plans to list in Hong Kong, with an IPO expected in 2027 pending regulatory review.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.